Fundraising FoxClavystBio — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief.
BiotechHealthtechMedical DevicesSan Jose, US
Adam Gridley(Executive Officer, Director)inKristen Howells(Executive Officer)inJosh Makower(Director)Tak Cheung(Director)inKarun D. Naga(Executive Officer, Director)
BoardLeighton Read(Director)
Co-investorsArboretum VenturesLightstone VenturesNew Enterprise Associates (NEA)SGInnovateEvonik Venture Capital GmbH
Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.
BiotechHealthtechLongevityCambridge, US
Ying Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)
BoardAlexandra Cantley(Director)inKhoo Shih(Director)
Co-investorsLong GameZAKA VCPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.